20121218

Know About Leukemia



Jaguar debuts a "Firesand" orange F-Type in North America


The F-TYPE line has three engine options, including a 5.0-liter supercharged V8
The F-TYPE line has three engine options, including a 5.0-liter supercharged V8
We learned all there is to know about the all-new Jaguar F-TYPE convertible at the 2012 Paris Motor Show. To add a little excitement to the North American debut of the car at last week's L.A. Auto Show, however, Jaguar showed its newest drop-top in a set of bright orange duds.
Jogging your memory quickly, the F-TYPE is the spiritual successor to the E-TYPE, one of the most iconic and visually-stunning cars of all time. While the convertible may or may not fill the monstrous boots of its predecessor, it is a dynamic two-seater in its own right. With nearly 500-hp on tap in its most powerful S tune, the F-TYPE's 3,521 pounds (1,597 kg) fire off to 60 mph (95.6 km/h) in as little as 4.2 seconds.
The model that Jaguar showed in L.A. is the 380-hp V6-powered S version with special-order Firesand paint. It also features the optional Design pack, with body-colored side sill extensions, front aero splitter and gloss black color-keyed rear valance, along with interior and exterior Black packs, which add gloss black accents and trim inside and out.
We've already covered the F-Type in depth, so we won't list off its specs all over again. The big story here is that it has made it to North America and has a new set of "Firesand" clothes to show for it. It will go on sale toward the middle of next year.
In order to optimize weight distribution, Jaguar put the battery and wiper fluid tank in t...
I wasn't the biggest fan of the F-Type when I first saw photos of it. So maybe it was the bright lights of the show, or my weary, sleep-deprived eyes, but it looked a helluva lot better in person. The Firesand color suits it well, in my opinion. Decide if you agree or disagree by taking a look at our full gallery.
Source: Jaguar

Europe’s nEUROn UCAV demonstrator makes its maiden flight

The nEUROn Unmanned Combat Aerial Vehicle (UCAV) demonstrator on its maiden flight
The nEUROn Unmanned Combat Aerial Vehicle (UCAV) demonstrator on its maiden flight
The European designed nEUROn Unmanned Combat Aerial Vehicle (UCAV) demonstrator successfully completed its maiden flight on December 1, 2012. The flight took place at Dassault Aviation’s flight test base in Istres in southern France and marks a milestone for the nEUROn program that was launched in 2005 by the French Defense Procurement Agency (DGA) that involves the collaboration of six European countries.
  • The nEUROn Unmanned Combat Aerial Vehicle (UCAV) demonstrator takes to the air for the fir...
  • The nEUROn Unmanned Combat Aerial Vehicle (UCAV) demonstrator takes off on its maiden flig...
  • The nEUROn Unmanned Combat Aerial Vehicle (UCAV) demonstrator being unveiled in January, 2...
Measuring 9.2 m (30 ft) long and boasting a wingspan of 12.5 m (41 ft), the stealth technology demonstrator is the first large size stealth platform designed in Europe. It has an empty weight of 5 tons (4.5 tonnes) and a maximum weight of 7 tons (6.3 tonnes). Powered by a Rolls-Royce Turbomeca “Adour” engine, the nEUROn can fly for three hours and reach a maximum speed of Mach 0.8.
With the aim of the program to develop expertise in advanced aeronautics amongst the participating countries and industries, the aircraft itself isn’t intended for serial production, but will be used to test various technologies for future UAVs and UCAVs, including Saab’s next-generation Gripen.
The nEUROn Unmanned Combat Aerial Vehicle (UCAV) demonstrator takes to the air for the fir...
France’s Dassault Aviation is serving as the nEUROn program’s prime contractor, with involvement from Alenia Aermacchi (Italy), Saab (Sweden), EADS-CASA (Spain), Hellenic Aerospace Industry (Greece), RUAG (Switzerland), and Thales (France).
Testing in France will continue until 2014, when it will be transferred to Vidsel in Sweden for a series of operational trials. It will then move onto Italy’s Perdadesfogu range for further testing focused on firing and stealth capabilities.
Sources: SaabDassault Aviation

Dear Profit Magazine Subscriber:
We are conducting a survey in order to improve our publication's technology and business information content. Will you please take a few minutes to answer some questions?
The survey should take no more than 10 minutes to complete. We think you will find the questions interesting and easy to answer. In most cases, a simple click of the mouse is all that is required.
Your individual answers will be kept strictly confidential and will be used only in combination with those of other survey respondents. Erdos & Morgan, the market research firm we have hired to conduct this study is bound by an industry code of ethics not to divulge any individual answers. If you have any concerns whatsoever, call David March, Executive VP Sales and Marketing of Erdos & Morgan, at 516-935-6959, or feel free to email me at jennifer.hamilton@oracle.com.
Erdos & Morgan has set up a website specifically for this study that you can access using the link below. Simply go to this site and enter the password below to participate in our study.
Internet URL: http://ErdosSurvey.com/Profit/survey 
Password: J7EGF

In appreciation for your efforts, all respondents who complete the survey will be entered into a drawing to win an Apple iPad.
Thank you very much for your cooperation. We hope to hear from you soon.
Regards,
Jennifer Hamilton Bingo
Publisher
Profit Magazine





Leukemia is cancer of the blood cells. It starts in the bone marrow, the soft tissue inside most bones. Bone marrow is where blood cells are made. When you are healthy, your bone marrow makes: •White blood cells, which help your body fight infection. •Red blood cells, which carry oxygen to all parts of your body. •Platelets, which help your blood clot. When you have leukemia, the bone marrow starts to make a lot of abnormal white blood cells, called leukemia cells. They don't do the work of normal white blood cells, they grow faster than normal cells, and they don't stop growing when they should. Over time, leukemia cells can crowd out the normal blood cells. This can lead to serious problems such as anemia, bleeding, and infections. Leukemia cells can also spread to the lymph nodes.

http://printer-friendly.adam.com/content.aspx?productId=117&pid=1&gid=000542&c_custid=758http://www.umm.edu/ency/article/000542.htm
http://www.emedicinehealth.com/leukemia-health/article_em.htm
http://oregon.providence.org/patients/healthconditionscare/leukemia/Pages/default.aspx?stagesofcare=treatment
http://www.nlm.nih.gov/medlineplus/ency/article/000570.htm
http://www.cancer.org/cancer/leukemia-acutelymphocyticallinadults/detailedguide/leukemia-acute-lymphocytic-what-is-all
http://www.multicare.org/home/leukemia-lymphoma
http://www.alegentcreighton.com/leukemia
http://www.ghc.org/kbase/topic.jhtml?docId=tv7433&print=true
http://www.kucancercenter.org/cancer-information/specialties-and-treatment/leukemia